Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial

IMPORTANCE: The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not increase survival. The Three or Six Colon Adjuvant (TOSCA) trial compared 3 months with 6 months...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Oncol
Asıl Yazarlar: Petrelli, Fausto, Labianca, Roberto, Zaniboni, Alberto, Lonardi, Sara, Galli, Fabio, Rulli, Eliana, Rosati, Gerardo, Corallo, Salvatore, Ronzoni, Monica, Cardellino, Giovanni Gerardo, Mattioli, Rodolfo, Mambrini, Andrea, Ciuffreda, Libero, Banzi, Maria, Pusceddu, Valeria, Maiello, Evaristo, Zampino, Maria, Zagonel, Vittorina, Marchetti, Paolo, Corsi, Domenico, Rimassa, Lorenza, Cinieri, Saverio, Sobrero, Alberto
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2020
Konular:
Brief Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7042800/
https://ncbi.nlm.nih.gov/pubmed/32053133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.6486
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller